Literature DB >> 23554495

The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury.

Adam D Bachstetter1, Rachel K Rowe, Machi Kaneko, Danielle Goulding, Jonathan Lifshitz, Linda J Van Eldik.   

Abstract

Neuropathology after traumatic brain injury (TBI) is the result of both the immediate impact injury and secondary injury mechanisms. Unresolved post-traumatic glial activation is a secondary injury mechanism that contributes to a chronic state of neuroinflammation in both animal models of TBI and human head injury patients. We recently demonstrated, using in vitro models, that p38α MAPK signaling in microglia is a key event in promoting cytokine production in response to diverse disease-relevant stressors and subsequent inflammatory neuronal dysfunction. From these findings, we hypothesized that the p38α signaling pathway in microglia could be contributing to the secondary neuropathologic sequelae after a diffuse TBI. Mice where microglia were p38α-deficient (p38α KO) were protected against TBI-induced motor deficits and synaptic protein loss. In wild-type (WT) mice, diffuse TBI produced microglia morphological activation that lasted for at least 7 d; however, p38α KO mice failed to activate this response. Unexpectedly, we found that the peak of the early, acute phase cytokine and chemokine levels was increased in injured p38α KO mice compared with injured WT mice. The increased cytokine levels in the p38α KO mice could not be accounted for by more infiltration of macrophages or neutrophils, or increased astrogliosis. By 7 d after injury, the cytokine and chemokine levels remained elevated in injured WT mice but not in p38α KO mice. Together, these data suggest that p38α balances the inflammatory response by acutely attenuating the early proinflammatory cytokine surge while perpetuating the chronic microglia activation after TBI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23554495      PMCID: PMC3667712          DOI: 10.1523/JNEUROSCI.5399-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  71 in total

1.  Toll/interleukin-1 receptor domain-containing adapter inducing interferon-β mediates microglial phagocytosis of degenerating axons.

Authors:  Suneil Hosmane; Million Adane Tegenge; Labchan Rajbhandari; Prech Uapinyoying; Nishant Ganesh Kumar; Nitish Thakor; Arun Venkatesan
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

2.  Neuroinflammatory responses after experimental diffuse traumatic brain injury.

Authors:  Brian Joseph Kelley; Jonathan Lifshitz; John Theodore Povlishock
Journal:  J Neuropathol Exp Neurol       Date:  2007-11       Impact factor: 3.685

3.  SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

Authors:  F C Barone; E A Irving; A M Ray; J C Lee; S Kassis; S Kumar; A M Badger; R F White; M J McVey; J J Legos; J A Erhardt; A H Nelson; E H Ohlstein; A J Hunter; K Ward; B R Smith; J L Adams; A A Parsons
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

Review 4.  Sterile inflammation: sensing and reacting to damage.

Authors:  Grace Y Chen; Gabriel Nuñez
Journal:  Nat Rev Immunol       Date:  2010-11-19       Impact factor: 53.106

5.  CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation.

Authors:  Erin G Reed-Geaghan; Julie C Savage; Amy G Hise; Gary E Landreth
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

6.  SB203580, a p38 mitogen-activated protein kinase inhibitor, fails to improve functional outcome following a moderate spinal cord injury in rat.

Authors:  D P Stirling; J Liu; W Plunet; J D Steeves; W Tetzlaff
Journal:  Neuroscience       Date:  2008-05-17       Impact factor: 3.590

7.  MAPKAPK-2 signaling is critical for cutaneous wound healing.

Authors:  Thusanth Thuraisingam; Yong Zhong Xu; Kalyn Eadie; Mitra Heravi; Marie-Cristine Guiot; Rony Greemberg; Matthias Gaestel; Danuta Radzioch
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

Review 8.  Modulation of immune response by head injury.

Authors:  Maria Cristina Morganti-Kossmann; Laveniya Satgunaseelan; Nicole Bye; Thomas Kossmann
Journal:  Injury       Date:  2007-11-28       Impact factor: 2.586

Review 9.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

Review 10.  The immunology of traumatic brain injury: a prime target for Alzheimer's disease prevention.

Authors:  Brian Giunta; Demian Obregon; Renuka Velisetty; Paul R Sanberg; Cesar V Borlongan; Jun Tan
Journal:  J Neuroinflammation       Date:  2012-08-01       Impact factor: 8.322

View more
  66 in total

1.  Salvianolic acid A attenuates early brain injury after subarachnoid hemorrhage in rats by regulating ERK/P38/Nrf2 signaling.

Authors:  Xiang Gu; Chengzhang Zheng; Qiaoying Zheng; Shuiyu Chen; Wei Li; Zhanfang Shang; Huabin Zhang
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Traumatic Brain Injury Causes Chronic Cortical Inflammation and Neuronal Dysfunction Mediated by Microglia.

Authors:  Kristina G Witcher; Chelsea E Bray; Titikorn Chunchai; Fangli Zhao; Shane M O'Neil; Alan J Gordillo; Warren A Campbell; Daniel B McKim; Xiaoyu Liu; Julia E Dziabis; Ning Quan; Daniel S Eiferman; Andy J Fischer; Olga N Kokiko-Cochran; Candice Askwith; Jonathan P Godbout
Journal:  J Neurosci       Date:  2021-01-15       Impact factor: 6.167

3.  Activation of Sphingosine-1-Phosphate Receptor 1 in the Spinal Cord Produces Mechanohypersensitivity Through the Activation of Inflammasome and IL-1β Pathway.

Authors:  Timothy M Doyle; Zhoumou Chen; Mariaconcetta Durante; Daniela Salvemini
Journal:  J Pain       Date:  2019-02-23       Impact factor: 5.820

4.  Post-Injury Administration of Galantamine Reduces Traumatic Brain Injury Pathology and Improves Outcome.

Authors:  Jing Zhao; Michael J Hylin; Nobuhide Kobori; Kimberly N Hood; Anthony N Moore; Pramod K Dash
Journal:  J Neurotrauma       Date:  2017-12-18       Impact factor: 5.269

5.  Closed head injury in an age-related Alzheimer mouse model leads to an altered neuroinflammatory response and persistent cognitive impairment.

Authors:  Scott J Webster; Linda J Van Eldik; D Martin Watterson; Adam D Bachstetter
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

6.  Acute over-the-counter pharmacological intervention does not adversely affect behavioral outcome following diffuse traumatic brain injury in the mouse.

Authors:  Jordan L Harrison; Rachel K Rowe; Bruce F O'Hara; P David Adelson; Jonathan Lifshitz
Journal:  Exp Brain Res       Date:  2014-04-24       Impact factor: 1.972

Review 7.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

8.  Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse.

Authors:  Jordan L Harrison; Rachel K Rowe; Timothy W Ellis; Nicole S Yee; Bruce F O'Hara; P David Adelson; Jonathan Lifshitz
Journal:  Brain Behav Immun       Date:  2015-01-10       Impact factor: 7.217

Review 9.  The contribution of astrocytes and microglia to traumatic brain injury.

Authors:  Ila P Karve; Juliet M Taylor; Peter J Crack
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

10.  Immune activation promotes depression 1 month after diffuse brain injury: a role for primed microglia.

Authors:  Ashley M Fenn; John C Gensel; Yan Huang; Phillip G Popovich; Jonathan Lifshitz; Jonathan P Godbout
Journal:  Biol Psychiatry       Date:  2013-10-25       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.